Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis

Trial Profile

A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs ANB 019 (Primary) ; ANB 019 (Primary)
  • Indications Generalised pustular psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GALLOP
  • Sponsors AnaptysBio
  • Most Recent Events

    • 08 Nov 2018 According to an AnaptysBio media release, data from this study is expected in mid 2019.
    • 07 Aug 2018 According to an AnaptysBio media release, data from this study is expected in early 2019.
    • 08 May 2018 Status changed from planning to recruiting, according to an AnaptysBio media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top